The Del Mar Consulting Group, Inc.
Disclaimer
Never invest in any stock unless you can
afford to lose your entire investment. The Del Mar Consulting Group, Inc. is
typically compensated by client companies with restricted shares of stock which may cause a conflict in
interest.
The information and content contained within this website or disseminated by either The Del Mar Consulting Group, Inc. and/or Robert Prag, its President (collectively hereinafter referred to as “DCG") is for informational purposes only and is not an offer to sell securities or a solicitation of offers to purchase securities and should not be construed to be investment advice. DCG is not a broker-dealer, registered investment adviser, financial analyst, investment broker, financial adviser, or any sort of professional that would be deemed as an individual someone would rely upon for investment advice, and DCG shall not be held liable for any investment or trading losses one may incur by using the information contained within this website or disseminated by DCG. You should not construe any of the material contained within this website or disseminated by DCG as business, financial, investment, trading, legal, regulatory, tax, or accounting advice, and you should consult your business adviser, attorney, and tax and accounting advisers concerning any contemplated transactions.
Information on this website or disseminated by DCG, including but not limited to any client company press releases, investor presentations, corporate overviews, newsletters, analysts' reports, etc. is obtained from DCG's client companies, public filings, or publicly available sources deemed to be reliable; however, DCG takes no responsibility for verifying the accuracy of such information and makes no representation that such information is accurate or complete and consequently it should not be relied upon as such. The information is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject DCG to any registration requirement within such jurisdiction or country. DCG reserves the right to add, modify or delete any information on this website at any time.
In general, given the developmental stage of DCG's client companies, as well as the lack of liquidity in shares of client companies, investing in such shares is highly speculative and carries a high degree of risk. Investing in microcap stocks is very risky due to extreme volatility. An investor in such securities should be prepared and able to bear loss of his or her entire investment and should perform extensive independent due diligence prior to any purchase or sale of securities.
The information contained in this website or disseminated by DCG may contain “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward looking statements.” Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated including (i) all of the risks and uncertainties associated with developmental businesses; (ii) any particular Clients' possible lack of capital and their ability to obtain capital as needed; (iii) intense competition for products and services within the Clients' industry; (iv) the timely development and market acceptance of the Clients' products, services or technologies; and (v) the successful integration of any acquisitions and lines of business. All information contained in this website or disseminated by DCG that may include forward-looking statements pertaining to future anticipated projected plans, performance and developments; and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. There are a number of important factors that could cause actual events or actual results of the client companies to differ materially from these indicated by such forward-looking statements, many of which can be found in the company clients' SEC filings at www.sec.gov. DCG and its company clients undertake no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of information disseminated by DCG.
DCG has been retained by its clients companies as a consultant in the investor relations field and for related services, and as such, the clients companies have compensated DCG by issuing restricted shares of the client company's common stock and/or making cash payments. DCG will profit from its investor relations activities for its client companies. From time to time, DCG and its officers and employees will own or acquire additional securities issued by its client companies and/or will dispose of securities issued by its client companies that they hold. DCG does not undertake any obligation to provide any information on purchases and/or sales of securities issued by its client companies.
Specific amounts of compensation paid to DCG are explicitly detailed as follows in order to be in full compliance with the Securities Act of 1933, Section 17(b):
DCG has been retained by MusclePharm Corp. (OTCBB: MSLP) ("MSLP") as a consultant in the investor relations field and for related services from February 21, 2013 through February 21, 2014, and pursuant to such, MSLP has agreed to issue to DCG 45,000 shares of restricted stock. MSLP has agreed to pay DCG an average monthly cash retainer of $6,000. From time to time, DCG and/or Robert Prag will own or acquire additional securities issued by MSLP and/or will dispose of securities issued by MSLP. This may create a conflict of interest. DCG and Robert Prag does not undertake any obligation to provide any information on purchases and/or sales of securities issued by MSLP.
DCG has been retained by Vycor Medical, Inc. (OTCBB: VYCO) ("VYCO") as a consultant in the investor relations field and for related services from November 30, 2012 through November 30, 2013, and pursuant to such, VYCO has agreed to issue to DCG 140,000 shares of restricted stock. VYCO has agreed to pay DCG an average monthly cash retainer of $7,200. From time to time, DCG and/or Robert Prag will own or acquire additional securities issued by VYCO and/or will dispose of securities issued by VYCO. This may create a conflict of interest. DCG and Robert Prag does not undertake any obligation to provide any information on purchases and/or sales of securities issued by VYCO.
Information on this website or disseminated by DCG, including but not limited to any client company press releases, investor presentations, corporate overviews, newsletters, analysts' reports, etc. is obtained from DCG's client companies, public filings, or publicly available sources deemed to be reliable; however, DCG takes no responsibility for verifying the accuracy of such information and makes no representation that such information is accurate or complete and consequently it should not be relied upon as such. The information is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject DCG to any registration requirement within such jurisdiction or country. DCG reserves the right to add, modify or delete any information on this website at any time.
In general, given the developmental stage of DCG's client companies, as well as the lack of liquidity in shares of client companies, investing in such shares is highly speculative and carries a high degree of risk. Investing in microcap stocks is very risky due to extreme volatility. An investor in such securities should be prepared and able to bear loss of his or her entire investment and should perform extensive independent due diligence prior to any purchase or sale of securities.
The information contained in this website or disseminated by DCG may contain “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward looking statements.” Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated including (i) all of the risks and uncertainties associated with developmental businesses; (ii) any particular Clients' possible lack of capital and their ability to obtain capital as needed; (iii) intense competition for products and services within the Clients' industry; (iv) the timely development and market acceptance of the Clients' products, services or technologies; and (v) the successful integration of any acquisitions and lines of business. All information contained in this website or disseminated by DCG that may include forward-looking statements pertaining to future anticipated projected plans, performance and developments; and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. There are a number of important factors that could cause actual events or actual results of the client companies to differ materially from these indicated by such forward-looking statements, many of which can be found in the company clients' SEC filings at www.sec.gov. DCG and its company clients undertake no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of information disseminated by DCG.
DCG has been retained by its clients companies as a consultant in the investor relations field and for related services, and as such, the clients companies have compensated DCG by issuing restricted shares of the client company's common stock and/or making cash payments. DCG will profit from its investor relations activities for its client companies. From time to time, DCG and its officers and employees will own or acquire additional securities issued by its client companies and/or will dispose of securities issued by its client companies that they hold. DCG does not undertake any obligation to provide any information on purchases and/or sales of securities issued by its client companies.
Specific amounts of compensation paid to DCG are explicitly detailed as follows in order to be in full compliance with the Securities Act of 1933, Section 17(b):
DCG has been retained by MusclePharm Corp. (OTCBB: MSLP) ("MSLP") as a consultant in the investor relations field and for related services from February 21, 2013 through February 21, 2014, and pursuant to such, MSLP has agreed to issue to DCG 45,000 shares of restricted stock. MSLP has agreed to pay DCG an average monthly cash retainer of $6,000. From time to time, DCG and/or Robert Prag will own or acquire additional securities issued by MSLP and/or will dispose of securities issued by MSLP. This may create a conflict of interest. DCG and Robert Prag does not undertake any obligation to provide any information on purchases and/or sales of securities issued by MSLP.
DCG has been retained by Vycor Medical, Inc. (OTCBB: VYCO) ("VYCO") as a consultant in the investor relations field and for related services from November 30, 2012 through November 30, 2013, and pursuant to such, VYCO has agreed to issue to DCG 140,000 shares of restricted stock. VYCO has agreed to pay DCG an average monthly cash retainer of $7,200. From time to time, DCG and/or Robert Prag will own or acquire additional securities issued by VYCO and/or will dispose of securities issued by VYCO. This may create a conflict of interest. DCG and Robert Prag does not undertake any obligation to provide any information on purchases and/or sales of securities issued by VYCO.
DCG has been retained by ChromaDex Corporation (OTCBB: CDXC) ("CDXC") as a consultant in the investor relations field and for related services from December 8, 2011 through January 31, 2014. Pursuant to two separate agreements (one dated December 8, 2011 and one dated January 31, 2013), CDXC has issued or agreed to issue to DCG a total of 612,000 restricted shares of CDXC's common stock, of which 240,000 shares are subject to forfeiture. CDXC paid DCG $42,000 cash on 12/14/2011 and has paid DCG monthly cash retainers of approximately $4,500 per month from December 2011 through December 2012. CDXC has agreed to pay DCG a monthly cash retainer of $3,600 per month for the period between January 2013 and June 2013 and $7,200 per month for the period between July 2013 and January 2014. Separately and unrelated to any compensation, Robert Prag, the President of DCG, acquired 535,714 shares of common stock directly from CDXC as a participant in a private placement offering completed on 5/20/2010 and separately acquired an additional 535,714 shares of common stock directly from CDXC through the exercise of a warrant on 12/3/2010. From time to time, DCG and Robert Prag will own or acquire additional securities issued by CDXC and/or will dispose of securities issued by CDXC. This may create a conflict of interest. DCG and Robert Prag does not undertake any obligation to provide any information on purchases and/or sales of securities issued by CDXC.
Use of DCG's or its client companies' websites, logos, themes, or other items contained in all information contained in this website or disseminated by DCG are prohibited without the express written consent of DCG and/or its client companies.
